Cargando…

Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study

OBJECTIVES: Fluoroquinolone-associated tendon ruptures are a recognised complication, but other severe collagen-associated adverse events may also be possible. Our objectives were to confirm the association of fluoroquinolones and tendon rupture, to clarify the potential association of fluoroquinolo...

Descripción completa

Detalles Bibliográficos
Autores principales: Daneman, Nick, Lu, Hong, Redelmeier, Donald A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4654346/
https://www.ncbi.nlm.nih.gov/pubmed/26582407
http://dx.doi.org/10.1136/bmjopen-2015-010077
_version_ 1782402042973650944
author Daneman, Nick
Lu, Hong
Redelmeier, Donald A
author_facet Daneman, Nick
Lu, Hong
Redelmeier, Donald A
author_sort Daneman, Nick
collection PubMed
description OBJECTIVES: Fluoroquinolone-associated tendon ruptures are a recognised complication, but other severe collagen-associated adverse events may also be possible. Our objectives were to confirm the association of fluoroquinolones and tendon rupture, to clarify the potential association of fluoroquinolones and retinal detachment, and to test for a potentially lethal association between fluoroquinolones and aortic aneurysms. SETTING: Population-based longitudinal cohort study in Ontario, Canada. PARTICIPANTS: Older adults turning 65 years between April 1 1997 and March 31 2012 were followed until primary outcome, death, or end of follow-up (March 31 2014). Fluoroquinolone prescriptions were measured as a time-varying covariate, with patients considered at risk during and for 30 days following a treatment course. PRIMARY OUTCOME MEASURES: Severe collagen-associated adverse events defined as tendon ruptures, retinal detachments and aortic aneurysms diagnosed in hospital and emergency departments. RESULTS: Among the 1 744 360 eligible patients, 657 950 (38%) received at least one fluoroquinolone during follow-up, amounting to 22 380 515 days of treatment. The patients experienced 37 338 (2.1%) tendon ruptures, 3246 (0.2%) retinal detachments, and 18 391 (1.1%) aortic aneurysms. Severe collagen-associated adverse events were more common during fluoroquinolone treatment than control periods, including tendon ruptures (0.82 vs 0.26/100-person years, p<0.001), retinal detachments (0.03 vs 0.02/100-person-years, p=0.003) and aortic aneurysms (0.35 vs 0.13/100-person-years, p<0.001). Current fluoroquinolones were associated with an increased hazard of tendon rupture (HR 3.13, 95% CI 2.98 to 3.28; adjusted HR 2.40, 95% CI 2.24 to 2.57) and an increased hazard of aortic aneurysms (HR 2.72, 95% CI 2.53 to 2.93; adjusted HR2.24, 95% CI 2.02 to 2.49) that were substantially greater in magnitude than the association of these outcomes with amoxicillin. The hazard of retinal detachment was marginal (HR 1.28, 95% CI 0.99 to 1.65; adjusted HR 1.47, 95% CI 1.08 to 2.00) and not greater in magnitude than that observed with amoxicillin. CONCLUSIONS: Fluoroquinolones are associated with subsequent tendon ruptures and may also contribute to aortic aneurysms.
format Online
Article
Text
id pubmed-4654346
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-46543462015-12-02 Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study Daneman, Nick Lu, Hong Redelmeier, Donald A BMJ Open Infectious Diseases OBJECTIVES: Fluoroquinolone-associated tendon ruptures are a recognised complication, but other severe collagen-associated adverse events may also be possible. Our objectives were to confirm the association of fluoroquinolones and tendon rupture, to clarify the potential association of fluoroquinolones and retinal detachment, and to test for a potentially lethal association between fluoroquinolones and aortic aneurysms. SETTING: Population-based longitudinal cohort study in Ontario, Canada. PARTICIPANTS: Older adults turning 65 years between April 1 1997 and March 31 2012 were followed until primary outcome, death, or end of follow-up (March 31 2014). Fluoroquinolone prescriptions were measured as a time-varying covariate, with patients considered at risk during and for 30 days following a treatment course. PRIMARY OUTCOME MEASURES: Severe collagen-associated adverse events defined as tendon ruptures, retinal detachments and aortic aneurysms diagnosed in hospital and emergency departments. RESULTS: Among the 1 744 360 eligible patients, 657 950 (38%) received at least one fluoroquinolone during follow-up, amounting to 22 380 515 days of treatment. The patients experienced 37 338 (2.1%) tendon ruptures, 3246 (0.2%) retinal detachments, and 18 391 (1.1%) aortic aneurysms. Severe collagen-associated adverse events were more common during fluoroquinolone treatment than control periods, including tendon ruptures (0.82 vs 0.26/100-person years, p<0.001), retinal detachments (0.03 vs 0.02/100-person-years, p=0.003) and aortic aneurysms (0.35 vs 0.13/100-person-years, p<0.001). Current fluoroquinolones were associated with an increased hazard of tendon rupture (HR 3.13, 95% CI 2.98 to 3.28; adjusted HR 2.40, 95% CI 2.24 to 2.57) and an increased hazard of aortic aneurysms (HR 2.72, 95% CI 2.53 to 2.93; adjusted HR2.24, 95% CI 2.02 to 2.49) that were substantially greater in magnitude than the association of these outcomes with amoxicillin. The hazard of retinal detachment was marginal (HR 1.28, 95% CI 0.99 to 1.65; adjusted HR 1.47, 95% CI 1.08 to 2.00) and not greater in magnitude than that observed with amoxicillin. CONCLUSIONS: Fluoroquinolones are associated with subsequent tendon ruptures and may also contribute to aortic aneurysms. BMJ Publishing Group 2015-11-18 /pmc/articles/PMC4654346/ /pubmed/26582407 http://dx.doi.org/10.1136/bmjopen-2015-010077 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Infectious Diseases
Daneman, Nick
Lu, Hong
Redelmeier, Donald A
Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study
title Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study
title_full Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study
title_fullStr Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study
title_full_unstemmed Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study
title_short Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study
title_sort fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study
topic Infectious Diseases
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4654346/
https://www.ncbi.nlm.nih.gov/pubmed/26582407
http://dx.doi.org/10.1136/bmjopen-2015-010077
work_keys_str_mv AT danemannick fluoroquinolonesandcollagenassociatedsevereadverseeventsalongitudinalcohortstudy
AT luhong fluoroquinolonesandcollagenassociatedsevereadverseeventsalongitudinalcohortstudy
AT redelmeierdonalda fluoroquinolonesandcollagenassociatedsevereadverseeventsalongitudinalcohortstudy